Stem-cell transplantation in multiple myeloma: how far have we come?

High-dose therapy (HDT) and autologous stem-cell transplantation (ASCT) has historically been an essential part of multiple myeloma (MM) management since early studies demonstrated its efficacy in relapsed disease, and subsequent phase III trials demonstrated better responses and improved survival w...

Descripción completa

Detalles Bibliográficos
Autores principales: Soekojo, Cinnie Y., Kumar, Shaji K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859676/
https://www.ncbi.nlm.nih.gov/pubmed/31798820
http://dx.doi.org/10.1177/2040620719888111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859676/
https://www.ncbi.nlm.nih.gov/pubmed/31798820
http://dx.doi.org/10.1177/2040620719888111

Ejemplares similares